NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Biotechnology · CAD

BriaCell Therapeutics Corp. (BCT.TO) Stock Analysis

BriaCell Therapeutics Corp. (BCT.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

BCT.TO

CA$4.93

+CA$0.06 (+1.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCT.TO with… →

BCT.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$4.84
Previous Close
CA$4.87
Day's Range
4.81–4.93
52-Week Range
3.68–20.40
Volume
3.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
CA$42.89M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.17
Financials (FY)
Revenue (FY)
CA$0.00
Net Income (FY)
−CA$4.79M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.70M
1-Year Return
−53.53%
Dividend and dates
Avg Volume
6.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCT.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.69%
2025−91.93%
2024−89.62%
2023+33.39%
2022−44.34%
2021+77.26%
2020−50.17%
2019−50.00%
2018−50.00%
2017−20.00%
2016 (partial year)−16.67%

As of September 4, 2026.

BCT.TO Revenue and Earnings by Fiscal Year

FY ends July
Fiscal yearRevenueNet incomeNet margin
2024CA$0.00−CA$4.79M—
2023CA$0.00−CA$20.30M—
2022CA$0.00−CA$26.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024CA$0.00—−CA$33.33M−CA$4.79M—
2023CA$0.00—−CA$23.27M−CA$20.30M—
2022CA$0.00—−CA$15.29M−CA$26.84M—

Annual figures as reported, in the company's reporting currency. As of July 31, 2024.

BCT.TO Valuation vs Biotechnology Median

Median of 656 stocks
MetricBCT.TOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values BriaCell Therapeutics Corp. (BCT.TO) at CA$42.89M. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for BCT.TO is CA$4.93, dated September 4, 2026. That is +CA$0.06 (+1.23%) against the previous close. Over the past 52 weeks the price has ranged from CA$3.68 to CA$20.40. The latest close sits 33.97% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to CA$0.00. The same year closed with a net loss of CA$4.79M. Profit margin runs at 0%. Trailing earnings per share are −1.17.

Across the 3 fiscal years on file, revenue moves from CA$0.00 in 2022 to CA$0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −53.53%. Across 10 years the annualized return works out at −53.00%. Beta against the wider market is reported at 1.53. Daily returns over the trailing 10 years annualize to a volatility of 9,477.1%.

Growth & Income

The record shows no dividend for BCT.TO.

The strongest complete calendar year on file is 2021 at +77.26%; the weakest is 2025 at −91.93%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −49.69%.

Peer Comparison

BriaCell Therapeutics Corp. (BCT.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BriaCell Therapeutics Corp. BCT.TO CA$42.89M —
Vertex Pharmaceuticals Incorporated VRTX CA$138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN CA$85.22B 20.5
argenx SE ARGX CA$64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BriaCell Therapeutics Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Visit website →